FY2026 EPS Estimates for MannKind Lowered by Leerink Partnrs

MannKind Co. (NASDAQ:MNKD) – Research analysts at Leerink Partnrs cut their FY2026 earnings per share estimates for MannKind in a research note issued on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will earn $0.22 per share for the year, down from their prior estimate of $0.23. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Several other brokerages also recently weighed in on MNKD. Leerink Partners initiated coverage on shares of MannKind in a research report on Monday, September 9th. They set an “outperform” rating and a $8.00 price target for the company. Royal Bank of Canada raised shares of MannKind from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $7.00 to $10.00 in a report on Thursday. Wells Fargo & Company began coverage on MannKind in a research report on Friday. They set an “overweight” rating and a $9.00 price objective for the company. StockNews.com cut MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, December 7th. Finally, Oppenheimer increased their price objective on shares of MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $8.88.

MannKind Stock Performance

NASDAQ:MNKD opened at $6.85 on Friday. The firm has a 50-day simple moving average of $6.76 and a two-hundred day simple moving average of $6.02. The firm has a market cap of $1.89 billion, a P/E ratio of 97.86 and a beta of 1.28. MannKind has a fifty-two week low of $3.17 and a fifty-two week high of $7.63.

Insider Activity

In related news, insider Stuart A. Tross sold 55,000 shares of MannKind stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the sale, the insider now owns 967,191 shares of the company’s stock, valued at approximately $7,099,181.94. This trade represents a 5.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven B. Binder sold 67,539 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $6.76, for a total transaction of $456,563.64. Following the sale, the director now directly owns 1,075,026 shares of the company’s stock, valued at approximately $7,267,175.76. This trade represents a 5.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 190,075 shares of company stock valued at $1,325,587 in the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On MannKind

Institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new position in MannKind during the second quarter worth $55,000. Brookstone Capital Management bought a new stake in MannKind in the second quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of MannKind by 22.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,946 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,816 shares during the last quarter. Renaissance Technologies LLC bought a new stake in MannKind during the 2nd quarter valued at about $67,000. Finally, Quantinno Capital Management LP purchased a new stake in MannKind in the 3rd quarter valued at about $85,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.